Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 31660987
Ito M, et al. (2019) Targeting PKCĪ¹-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Commun Signal 17, 137 31660987
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S144-p - PAK1 (human)
Modsite: sNsQKyMsFtDksAE SwissProt Entrez-Gene
Orthologous residues
PAK1 (human): S144‑p, PAK1 (mouse): S144‑p, PAK1 (rat): S144‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma
Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Mouse xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
osimertinib no change compared to control
IPA-3, osimertinib no change compared to control
IPA-3 decrease
Auranofin decrease
Auranofin, IPA-3 decrease
OTSSP167 decrease
Auranofin, OTSSP167 decrease
Auranofin, Trametinib decrease
Downstream Regulation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced
Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation
Associated Diseases
Diseases Alterations Comments
non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

S204-p - PAK1 (human)
Modsite: tKsVyTRsVIEPLPV SwissProt Entrez-Gene
Orthologous residues
PAK1 (human): S204‑p, PAK1 (mouse): S204‑p, PAK1 (rat): S203‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma
Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Mouse xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OTSSP167 decrease
Auranofin decrease
Auranofin, OTSSP167 decrease
IPA-3 decrease
Auranofin, IPA-3 decrease
osimertinib decrease
IPA-3, osimertinib decrease
Downstream Regulation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced
Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation
Associated Diseases
Diseases Alterations Comments
non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

T212-p - PAK1 (human)
Modsite: VIEPLPVtPtRDVAt SwissProt Entrez-Gene
Orthologous residues
PAK1 (human): T212‑p, PAK1 (mouse): T212‑p, PAK1 (rat): T211‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma
Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Mouse xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OTSSP167 decrease
Auranofin decrease
Auranofin, OTSSP167 decrease
IPA-3 decrease
Auranofin, IPA-3 decrease
osimertinib decrease
IPA-3, osimertinib decrease
Downstream Regulation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced
Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation
Associated Diseases
Diseases Alterations Comments
non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth

T423-p - PAK1 (human)
Modsite: PEQSkRstMVGtPYW SwissProt Entrez-Gene
Orthologous residues
PAK1 (human): T423‑p, PAK1 (mouse): T423‑p, PAK1 (rat): T422‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell squamous cell lung carcinoma
Relevant cell lines - cell types - tissues:  HCC827 (pulmonary), NCI-H23 (pulmonary), NCI-H520 (squamous)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Mouse xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
osimertinib no change compared to control
IPA-3, osimertinib no change compared to control
IPA-3 decrease
Auranofin decrease
Auranofin, IPA-3 decrease
OTSSP167 decrease
Auranofin, OTSSP167 decrease
Downstream Regulation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced
Comments:  Inhibitors decreased the tumor growth by inhibiting the phosphorylation
Associated Diseases
Diseases Alterations Comments
non-small cell lung cancer increased Inhibitors of PAK1-inhibits the tumor growth